US longevity biotech NOVOS has reported positive findings from a randomised, double-blind, placebo-controlled clinical trial investigating the effects of its NOVOS Core supplement on cardiovascular health.
The STAMINA trial, led by Professor Christian Heiss at the University of Surrey, found that six months of daily supplementation improved three measures of vascular health in healthy adults aged 40 and older.
Published in European Heart Journal Open this month, the study included 61 participants: 33 received NOVOS Core and 28 took a matched placebo.
Compared with placebo, the supplement group showed a 2.9 percentage-point improvement in flow-mediated dilation (FMD), a measure of blood vessel function and a 1.18 m/s reduction in pulse wave velocity, indicating improved arterial flexibility.
Systolic blood pressure also decreased, with an adjusted difference of 6.1mmHg between the supplement and placebo groups after six months.
Notably, blood vessel function improved within an hour of the first serving.
Cholesterol and other blood lipid levels remained unchanged throughout the study.
Targeting the hallmarks of ageing
NOVOS Core is a daily 15 g drink mix containing 12 natural ingredients selected to target multiple biological processes associated with ageing.
Its formulation is based on the 12 biological hallmarks of ageing, aiming to support healthspan, lifespan and whole-body health.
The company said the findings provide early human evidence for its approach of addressing several ageing-related mechanisms simultaneously, rather than focusing on individual pathways.
Founded in 2019, NOVOS has developed a broader longevity-focused portfolio that includes NOVOS Boost, an NMN supplement, NOVOS Vital gummies and NOVOS Bars, along with its NOVOS Age biological-age testing service and NOVOS Life digital guidance platform.
Earlier research has included laboratory work investigating cellular DNA damage and preclinical studies exploring lifespan in mice, with the STAMINA trial representing a further step towards evaluating its formulations in humans.
Further research planned
NOVOS supported the STAMINA study by supplying the supplement and placebo and contributing towards research costs.
While the results are encouraging, the researchers emphasised that the trial measured cardiovascular biomarkers rather than clinical outcomes and larger studies are needed to establish whether the improvements translate into meaningful longer-term health benefits.
NOVOS is now evaluating further research into the potential effects of its Core formulation on muscle function, brain health and cognition, skin and biological ageing.
